Latest Breaking News On - Onc201 i - Page 1 : vimarsana.com

Stephen Bagley, MD, MSCE, discusses the phase 3 ACTION trial evaluating ONC201 in H3K27M-mutant diffuse midline gliomas.

United statesStephen bagleyUniversity of pennsylvania hospitalPennsylvania hospitalPenn medicinePhase 3 action trialOnc201 iH3k27m mutant diffuse midline gliomas